

Programmes - Oral Presentations

NZBCS-2021: the Virtual NZ Breast Cancer Symposium

Friday 19th November 2021, 8:00am – 4:30pm

Web: <http://www.nzbc.org.nz>; Email: nabc@aut.ac.nz

Organised by



In association with



Hosted by



Gold Sponsor



Silver Sponsor



Silver Sponsor



Bronze Sponsor

Date: Friday November 19, 2021		
8:00 – 8:30 Opening Ceremony		
<p>Our VIPs include:</p> <ul style="list-style-type: none"> • Professor Derek McCormack, the Vice-Chancellor of the Auckland University of Technology. • Professor Fiona Brooks, Pro Vice-Chancellor and Dean, Faculty of Health and Environmental Sciences, Auckland University of Technology. • Ah-Leen Rayner, the CEO of Breast Cancer Foundation NZ. • Dr Valance Smith, Assistant Pro-Vice Chancellor (Māori Advancement), the Auckland University of Technology. 		
8:30 – 8:35 Welcome from Associate Professor Dong-Xu Liu, the President of NZABC®		
8:35 – 9:20 Opening Keynotes (Chair: Dr Linda Peters)		
<p>Professor Ian Ellis, BMedSci, BM MS, FRCPath, the University of Nottingham; Nottingham University Hospitals, UK: [21004] Selected highlights from the 2019 5th Edition of the WHO classification of breast tumours</p>		
<p>Professor Michael Eccles, BSc(Hons)(Massey), PhD(Otago), the University of Otago, New Zealand: [21002] How might Māori benefit from molecular profiling for precision cancer therapies in breast cancer in NZ?</p>		
9:20 – 9:25 Lounge Transition		
9:25 – 10:30 Parallel Sessions: Lounge A - Session A1		
Chairs: Prof Graham Ball, UK & Associate Prof Mandeep Kaur, South Africa		
9:25 – 9:35	Prof Graham Ball	[21008] In Silico Modelling of the TP53 Pathway in Breast cancer Using System Biology Approaches

The NZBCS-2021 Programmes - Oral Presentations

9:35 – 9:45	Prof Ingunn Holen	[21009] Challenges of targeting tumour cell dormancy for improved breast cancer outcome – lessons from models of bone metastasis
9:45 – 9:55	Karen Bartholomew	[21072] Gaps in the provision of radiotherapy for early breast cancer
9:55 – 10:00	Fiona J McDonald	[21049] Epithelial sodium channel regulates breast cancer cell proliferation
10:00 – 10:05	Gabriella B.H. Palmal	[21063] The Roles of miRNA-128 and miRNA-223 in Cholesterol-Mediated Drug Resistance in Breast Cancer
10:05 – 10:10	Shanen Perumal	[21060] Elucidating the role of cholesterol pathways in the epithelial to mesenchymal transition in breast cancer cells
10:10 – 10:15	Nada Emad	[21054] Role of proton pump inhibitors in decreasing chemoresistance of triple negative breast cancer: Potential crosstalk between cancer stem cells and Wnt/ β -catenin pathway
10:15 – 10:20	Imaobong Christopher Etti	[21074] Naturally occurring flavonoids as promising inhibitors of breast cancer metastasis: an in silico approach
10:20 – 10:25	Yu Gao	[21080] Bufalin and doxorubicin combination therapy to target trastuzumab-resistant HER2 positive breast cancer
10:25 – 10:30	Q&A	
9:25 – 10:30	Parallel Sessions: Lounge B - Session B1 Chairs: Dr Theresa Vincent, Sweden & Jorge Illarramendi, Spain	
9:25 – 9:35	Ivonne Nel	[21067] Analysis of disseminated tumour cells (DTCs) in primary and recurrent breast cancer patients with various molecular subtypes
9:35 – 9:45	Prof Yuval Shaked	[21011] The plasticity of stromal cells at the tumour microenvironment and their contribution to tumor fate
9:45 – 9:55	Theresa Vincent	[21070] A novel way of targeting metastatic disease
9:55 – 10:00	Jorge Illarramendi	[21064] Evaluation of thromboembolic events associated to COVID-19 in a cohort of breast cancer survivors during the pandemic waves of the disease
10:00 – 10:05	Hansje P. Smeele	[21053] Patient-reported outcome measures for assessing breast sensation after mastectomy
10:05 – 10:10	Giuseppe Di Bella	[21051] Observational retrospective clinical study on the application of the Di Bella Method (DBM) from 2004 to today on breast carcinomas. Preliminary data on survival improvement, objective response and performance status
10:10 – 10:20	Cynthia A. Zahnow	[21037] A Novel Epigenetic Therapy Approach Targets the Tumor Immune Microenvironment of Murine Breast and Ovarian Cancers
10:20 – 10:25	Naazyiah Abdulla	[21061] Characterising the role of cholesterol in hypoxia-induced epithelial-mesenchymal transition in breast cancer
10:25 – 10:30	Q&A	
10:30- 10:40	Tea break	
10:40 – 11:25	Keynotes (Chair: Dr Linda Peters)	
Professor Jane Visvader, BSc (Hons), PhD Adelaide, Walter and Eliza Hall Institute, Australia: [21005] Getting a breast of cancer through understanding the mammary epithelial hierarchy		

The NZBCS-2021 Programmes - Oral Presentations

<p>Professor Sarah-Jane Dawson, MBBS (Hons), FRACP, PhD (Cantab), Peter MacCallum Cancer Centre, Melbourne, Australia: [21001] Tracking residual disease in breast cancer using liquid biopsies</p>		
<p>11:25 – 11:30 Lounge Transition</p>		
<p>11:30 – 12:25 Parallel Sessions: Lounge A - Session A2 Chairs: Prof Jianming Xu, USA & Prof Malathy Shekhar, USA</p>		
11:30 – 11:40	A/Prof Yihong Wang	[21019] Microinvasive breast cancer and the sentinel lymph node biopsy conundrum
11:40 – 11:50	A/Professor David P. Turner	[21050] Nutritional Non-Enzymatic Glycooxidation during Puberty Modifies the Breast Microenvironment to Alter Mammary Gland Development
11:50 – 12:00	Prof Jianming Xu	[21018] Uncovering the cell lineage-determined aggressiveness of HER2-caused breast cancer subtypes in a genetic mouse model system
12:00 – 12:10	Prof Malathy Shekhar	[21024] Platinum sensitivity of triple negative breast cancer cells is not affected by adaptive PARP inhibitor resistance
12:10 – 12:15	Sarah RA McQueen	[21069] The influence of overexpressed epithelial sodium channel in breast cancer cells
12:15 – 12:20	J. Clegg	[21031] Validating the Potential of starPEG-Heparin Hydrogels as an ex vivo Drug Testing System for Breast Cancer
12:20 – 12:25	Q&A	
<p>11:30 – 12:25 Parallel Sessions: Lounge B - Session B2 Chairs: Dr Yan Li, New Zealand & Prof Consolato M. Sergi, Canada</p>		
11:30 – 11:40	A/Prof Todd W. Miller	[21020] Mechanistic insight into estrogen therapy for breast cancer
11:40 – 11:50	Prof Masakazu Toi	[21014] Adjuvant therapy for HER2-negative luminal diseases
11:50 – 12:00	Prof Consolato M. Sergi	[21039] Diethylstilbestrol may use abnormal TWSG1 and BMP-signalling pathways in forming cysts and hyperplastic lesions
12:00 – 12:10	A/Prof Partha Roy	[21026] Intervention of MRTF-SRF transcriptional axis leads to impairment in metastatic colonization of breast cancer cells.
12:10 – 12:15	Ji He	[21073] Establishment of SPAG5 gene knockout breast cancer cell lines using CRISPR-Cas9 technology
12:15 – 12:20	Adam W Ware	[21052] Epithelial sodium channel (ENaC) influences breast cancer cell morphology and stiffness
12:20 – 12:25	Q&A	
<p>12:25 -12:55 PM Lunch break; e-Poster Session</p>		
<p>12:55 – 13:25 Technical Seminars by Sponsors</p>		
12:55 – 13:05	Gold Sponsor	QIAGEN
13:05 – 13:13	Silver Sponsor	Mediray
13:13 – 13:21	Silver Sponsor	AstraZeneca
12:21 – 13:25	Bronze Sponsor	Abcam

The NZBCS-2021 Programmes - Oral Presentations

13:25 – 14:10 Keynotes (Chair: Dr Linda Peters)		
<p style="text-align: center;">Professor Ross Lawrenson, MBBS London, MD London, FRCGP, FFPH, FAFPHM, Medical Research Centre, University of Waikato; Waikato District Health Board, Hamilton, New Zealand:</p> <p style="text-align: center;">[21003] Characteristics and outcomes from metastatic breast cancer in NZ women</p>		
<p style="text-align: center;">Professor Ian Campbell, BSc(Hons), PhD, Peter MacCallum Cancer Centre, Melbourne, Melbourne, Australia:</p> <p style="text-align: center;">[21006] The MAGIC study: Toward mainstreaming germline and tumour sequencing of newly diagnosed breast cancer</p>		
14:10 – 14:15 Lounge Transition		
<p style="text-align: center;">14:15 – 15:15 Parallel Sessions: Lounge A - Session A3</p> <p style="text-align: center;">Chairs: A/Prof David Gallego-Ortega, Australia & Dr Elena Harjes, New Zealand</p>		
14:15 – 14:25	Oliver W. Scott	[21013] Use of beta blockers and death from breast cancer in New Zealand breast cancer patients
14:25 – 14:35	David Gallego-Ortega	[21036] Immune regulation of the pre-metastatic niche formation in triple-negative breast cancer
14:35 – 14:45	Hanna van Waart	[21047] Exercise during the cancer continuum
14:45 – 14:55	Elena Harjes	[21065] Inhibition of APOBEC3 deaminase activity using modified DNA with the goal to suppress cancer evolution and delay drug resistance
14:55 – 15:00	Wey Qi Chin	[21043] Epithelial-mesenchymal plasticity & breast cancer: a role for the epithelial sodium channel
15:00 – 15:05	Rachelle E Steyn	[21076] F-18 FDG PET/CT for characterisation of Locally Advanced Breast Cancer in a Low-Middle Income Setting
15:05 – 15:10	Katsutoshi Enokido	[21062] The study of false negative fine needle aspiration cytology in axillary lymph node in breast cancer
15:10 – 15:15	Q&A	
<p style="text-align: center;">14:15 – 15:15 Parallel Sessions: Lounge B - Session B3</p> <p style="text-align: center;">Chairs: A/Prof Evelyn Sattlegger, New Zealand & Dr Honor Hugo, Australia</p>		
14:15 – 14:25	Logan C Walker	[21029] Evaluation of copy number variants as modifiers of breast cancer risk for BRCA1 and BRCA2 pathogenic variant carriers
14:25 – 14:35	Honor J. Hugo	[21075] Androgens antagonise the promotional effect of oestrogen on the mammographic density of patient-derived explants of human breast tissue
14:35 – 14:45	Stephen M.F. Jamieson	[21023] Genetic determinants of sensitivity and resistance to the antibody-drug conjugate T-DM1 in HER2-positive breast cancer
14:45 – 14:55	Kejia Khoo	[21046] Breast tissue displacement between prone and supine
14:55 – 15:00	Jocelyn Lippey	[21066] “Linking risk with screening” –Evaluation of an online decision aid for risk stratified breast screening within current BreastScreen clients
15:00 – 15:05	Evelyn Sattlegger	[21071] Testing the suitability of a novel drug target for disrupting a signalling pathway that is relevant for breast cancer cell growth and survival
15:05 – 15:10	Jing Huang	[21032] Prediabetic D-glucose levels promotes oncogenic phenotype of immortalized human mammary epithelial cells through stimulating TFF3 levels <i>in vitro</i>

The NZBCS-2021 Programmes - Oral Presentations

15:10 – 15:15	Q&A	
15:15 – 15:25	Tea break	
15:25 – 16:25	Parallel Sessions: Lounge A - Session A4 Chairs: Prof Ui-soon Khoo, Hong Kong & A/Prof Elizabeth Caldon, Australia	
15:25 – 15:35	A/Prof Elizabeth Caldon	[21030] Selective targeting in basal-like breast cancers with combination PARP and CDK2 inhibitors
15:35 – 15:45	Olivia K Burn	[21077] Glycolipid-peptide conjugate vaccines elicit CD8+ T cell responses and prevent breast cancer metastasis
15:45 – 15:55	Heather E Cunliffe	[21068] Investigating the Clinical Significance of Fibroblast Growth Factor Inducible 14 in Breast Cancer
15:55 – 16:00	Leung MH	[21044] Combined use of Ivabradine and Olaparib as a novel therapeutic strategy for triple-negative breast cancer
16:00 – 16:10	Prof Ui-soon Khoo	[21058] Targeting androgen receptor in BQ323636.1 overexpressing ER+ breast cancer to overcome aromatase inhibitor resistance
16:10 – 16:15	A. G. R. G. Jinadasa	[21082] Statins as a potential anticancer agent in breast cancer: a systematic review of BC cell line studies
16:15 – 16:20	Q&A	
15:25 – 16:25	Parallel Sessions: Lounge B - Session B4 Chairs: A/Prof Jo Perry, New Zealand & Dr Sarah D Diermeier, New Zealand	
15:25 – 15:35	Xiao-Yang Chen	[21040] Stroma with a dispersed thin collagen profile promotes the formation of tertiary lymphoid structures around breast ductal carcinoma in situ
15:35 – 15:45	Sarah D Diermeier ¹	[21025] The long non-coding RNA hMaTAR17 drives breast cancer growth and may act as a new regulator of cancer metabolism
15:45 – 15:55	Yue Wang	[21048] Targeting human growth hormone in breast cancer: development of long-acting growth hormone receptor antagonists
15:55 – 16:00	Ho Tsoi	[21045] Targeting CHK2 to reverse tamoxifen resistance by reducing BQ323636.1 in ER-positive breast cancer
16:00 – 16:10	In Kyoung Lim	[21016] Dissection of cancer cell growth and cancer invasion in TNBC cells via mTORc1 and mTORc2 signaling regulated by BTG2/Tis21 gene
16:10 – 16:15	Akalanka H. M. K	[21007] A study on stressful lifestyle, cortisol concentrations and breast cancer risk
16:15 – 16:20	Q&A	
16:20 – 16:25	Networking	
16:25 – 16:30	Closing Remarks	
16:30	End of the NZBCS-2021	